An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Passage Bio, Inc. (NASDAQ: PASG) will present at Chardan’s 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit. The event features William Chou, M.D., president, and CEO, and Eden Fucci, SVP of technical operations, in a virtual fireside chat on April 29, 2024. Investors can watch the webcast on Passage Bio's website.
Passage Bio, Inc. (NASDAQ: PASG) parteciperà al 8° Summit Annuale di Chardan sulla Medicina Genetica e la Produzione di Terapie Cellulari. L'evento includerà una conversazione informale virtuale il 29 aprile 2024, con William Chou, M.D., presidente e amministratore delegato, e Eden Fucci, vicepresidente senior delle operazioni tecniche. Gli investitori possono seguire il webcast sul sito web di Passage Bio.
Passage Bio, Inc. (NASDAQ: PASG) presentará en la 8ª Cumbre Anual de Medicina Genética y Fabricación de Terapias Celulares de Chardan. El evento contará con William Chou, M.D., presidente y CEO, y Eden Fucci, VP sénior de operaciones técnicas, en una charla virtual informal el 29 de abril de 2024. Los inversores pueden ver la transmisión en vivo en la página web de Passage Bio.
Passage Bio, Inc. (NASDAQ: PASG)는 차르단의 제8회 유전의학 및 세포치료제 제조 서밋에 참석할 예정입니다. 이 행사는 2024년 4월 29일 윌리엄 추, M.D., 회장 겸 CEO, 에덴 푸치, 기술 운영 담당 부사장이 참여하는 가상 구들장 토론을 특징으로 합니다. 투자자들은 Passage Bio의 웹사이트에서 웹캐스트를 시청할 수 있습니다.
Passage Bio, Inc. (NASDAQ: PASG) interviendra lors du 8ème Sommet Annuel de Chardan sur les Médicines Génétiques et la Fabrication de Thérapies Cellulaires. L'événement mettra en avant un débat informel virtuel le 29 avril 2024 avec William Chou, M.D., président et PDG, et Eden Fucci, vice-présidente senior des opérations techniques. Les investisseurs peuvent regarder le webcast sur le site web de Passage Bio.
Passage Bio, Inc. (NASDAQ: PASG) wird auf dem 8. jährlichen Genetik-Medizin und Zelltherapie-Herstellungs-Gipfel von Chardan präsentieren. Das Ereignis stellt eine virtuelle Kamingespräch am 29. April 2024 mit William Chou, M.D., Präsident und CEO, und Eden Fucci, Senior Vice President der technischen Betriebe, in den Mittelpunkt. Investoren können die Übertragung auf der Webseite von Passage Bio ansehen.
Positive
None.
Negative
None.
PHILADELPHIA, April 22, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced that William Chou, M.D., president and chief executive officer, and Eden Fucci, senior vice president of technical operations, will participate in a virtual fireside chat at Chardan’s 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit on Monday, April 29, 2024 at 9:00 a.m. ET.
A live webcast of the event will be available on the Investors & Media section of Passage Bio’s website at investors.passagebio.com. A replay of the presentation will be available for 30 days following the event.
About Passage Bio
Passage Bio (Nasdaq: PASG) is a clinical stage genetic medicines company on a mission to improve the lives of patients with neurodegenerative diseases. Our primary focus is the development and advancement of cutting-edge, one-time therapies designed to target the underlying pathology of these conditions. Passage Bio’s lead product candidate, PBFT02, seeks to treat neurodegenerative conditions, including frontotemporal dementia, by elevating progranulin levels to restore lysosomal function and slow disease progression.
To learn more about Passage Bio and our steadfast commitment to protecting patients and families against loss in neurodegenerative conditions, please visit: www.passagebio.com.
Passage Bio Media: Mike Beyer Sam Brown Inc. Healthcare Communications 312.961.2502 mikebeyer@sambrown.com
FAQ
When will Passage Bio participate in Chardan’s 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit?
Passage Bio will participate in the summit on Monday, April 29, 2024 at 9:00 a.m. ET.
Who will be featured in the virtual fireside chat at the event?
William Chou, M.D., president and chief executive officer, and Eden Fucci, senior vice president of technical operations, will participate in the fireside chat.
Where can investors watch the live webcast of the event?
Investors can watch the live webcast on the Investors & Media section of Passage Bio’s website at investors.passagebio.com.
How long will the replay of the presentation be available?
The replay of the presentation will be available for 30 days following the event.
passage bio, inc., a genetic medicines company, develops transformative therapies for rare monogenic central nervous system (cns) diseases. the company develops pbgm01, which utilizes a proprietary, aavhu68 capsid to deliver to the brain and peripheral tissues a functional glb1 gene encoding lysosomal acid beta-galactosidase (ã-gal) for infantile gm1; pbft02, which utilizes an aav1 capsid to deliver to the brain a functional granulin, or grn, gene encoding progranulin for the treatment of ftd caused by a deficiency of progranulin; and pbkr03, which utilizes a proprietary, aavhu68 capsid to deliver to the brain and peripheral tissues a functional galc gene encoding the hydrolytic enzyme galactosylceramidase, for infantile krabbe disease. it has a strategic research collaboration with the trustees of the university of pennsylvania's gene therapy program; and collaboration agreement, and a development services and clinical supply agreement with catalent maryland, inc. the company was fou
